Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, shared insight on a study she and colleagues conducted to assess the impact of social determinants of health in the context of germline genetic testing for triple-negative breast cancer in the community oncology setting.
Transcript
Which social determinants of health were most impactful on germline genetic testing rates among patients in the study?
So in this study, the one that really came up to the top was race. Black patients really had lower testing rates than White patients or Asian patients, actually. And that is something that we need to understand more why that's happening. And they have higher rates of triple negative breast cancer, so we need to understand more about that.
The other thing that was significant was the type of insurance people had. So the testing rates were higher for people who had private insurance or Medicaid, and it was lower for Medicare and private pay. And so, why is that? And can we affect that piece? This information might help us address some of these.
There were also a few other things that were significant, like the region in which a patient was, and age. There was a small difference in age—I think 4 and a half years between those who were tested and those who were not tested, so younger patients were more likely to get tested.
Can you discuss the overall importance of studying germline genetic testing uptake in the community oncology setting?
Well, first, I think we did not even understand what our testing rate was in the community oncology setting in this population. So it actually took some work to look at medical records, where are things documented, where things weren't documented. So learning that piece was really important, and and I think we learned a lot about where data is. I mean, people get tested before they even come to the oncologist, and does that information come over to the oncologist? So we learned a lot about that—about where it's documented and how to better [it, and] what the best practice is for that. And then, communication with our practices. All of the practices that participated in this study were practices that had a strong genetics program, and they're part of our GREAT network, which stands for genetic risk evaluation and testing. So it's a program a network of genetic providers. And so we have a strong genetic core in those practices, but we learned a lot about that we still need to work on with our with our oncologists and other other providers to make sure that these patients are getting what they need.
Social Determinants of Health Impact Germline Testing Rates Among Patients With TNBC
Rose McNulty
Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, shared insight on a study of social determinants of health in the context of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting.
Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, shared insight on a study she and colleagues conducted to assess the impact of social determinants of health in the context of germline genetic testing for triple-negative breast cancer in the community oncology setting.
Transcript
Which social determinants of health were most impactful on germline genetic testing rates among patients in the study?
So in this study, the one that really came up to the top was race. Black patients really had lower testing rates than White patients or Asian patients, actually. And that is something that we need to understand more why that's happening. And they have higher rates of triple negative breast cancer, so we need to understand more about that.
The other thing that was significant was the type of insurance people had. So the testing rates were higher for people who had private insurance or Medicaid, and it was lower for Medicare and private pay. And so, why is that? And can we affect that piece? This information might help us address some of these.
There were also a few other things that were significant, like the region in which a patient was, and age. There was a small difference in age—I think 4 and a half years between those who were tested and those who were not tested, so younger patients were more likely to get tested.
Can you discuss the overall importance of studying germline genetic testing uptake in the community oncology setting?
Well, first, I think we did not even understand what our testing rate was in the community oncology setting in this population. So it actually took some work to look at medical records, where are things documented, where things weren't documented. So learning that piece was really important, and and I think we learned a lot about where data is. I mean, people get tested before they even come to the oncologist, and does that information come over to the oncologist? So we learned a lot about that—about where it's documented and how to better [it, and] what the best practice is for that. And then, communication with our practices. All of the practices that participated in this study were practices that had a strong genetics program, and they're part of our GREAT network, which stands for genetic risk evaluation and testing. So it's a program a network of genetic providers. And so we have a strong genetic core in those practices, but we learned a lot about that we still need to work on with our with our oncologists and other other providers to make sure that these patients are getting what they need.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Telemedicine’s Evolution and Expanding Access to Obesity, Specialty Care
February 11th 2025George Jones of UpScript Health discusses telemedicine's evolution from basic e-prescribing to real-time video consultations, expanding treatment beyond primary care.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Telemedicine’s Evolution and Expanding Access to Obesity, Specialty Care
February 11th 2025George Jones of UpScript Health discusses telemedicine's evolution from basic e-prescribing to real-time video consultations, expanding treatment beyond primary care.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More